CY1120564T1 - Υδατικα εναιωρηματα tmc278 - Google Patents

Υδατικα εναιωρηματα tmc278

Info

Publication number
CY1120564T1
CY1120564T1 CY20181100428T CY181100428T CY1120564T1 CY 1120564 T1 CY1120564 T1 CY 1120564T1 CY 20181100428 T CY20181100428 T CY 20181100428T CY 181100428 T CY181100428 T CY 181100428T CY 1120564 T1 CY1120564 T1 CY 1120564T1
Authority
CY
Cyprus
Prior art keywords
tmc278
aquatic
suspensions
pharmaceutical compositions
therapeutic
Prior art date
Application number
CY20181100428T
Other languages
English (en)
Inventor
Lieven Elvire Colette Baert
Willy Maria Albert Carlo Dries
Laurent Bruno Schueller
Marc Karel Jozef FRANÇOIS
Peter Jozef Maria Van Remoortere
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120564(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of CY1120564T1 publication Critical patent/CY1120564T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

Η εφεύρεση αυτή αφορά σε φαρμακευτικές συνθέσεις για χορήγηση μέσω ενδομυϊκής ή υποδόριας ένεσης, που περιλαμβάνουν μικροσωματίδια ή νανοσωματίδια της ένωσης NNRTI TMC278, εναιωρούμενα σε έναν υδατικό, φαρμακευτικώς αποδεκτό, φορέα και στη χρήση των εν λόγω φαρμακευτικών συνθέσεων στη θεραπευτική αντιμετώπιση και την προφύλαξη από τη μόλυνση από τον ιό HIV.
CY20181100428T 2006-06-23 2018-04-24 Υδατικα εναιωρηματα tmc278 CY1120564T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06115938 2006-06-23
EP07786802.4A EP2040671B1 (en) 2006-06-23 2007-06-22 Aqueous suspensions of tmc278
PCT/EP2007/056230 WO2007147882A2 (en) 2006-06-23 2007-06-22 Aqueous suspensions of tmc278

Publications (1)

Publication Number Publication Date
CY1120564T1 true CY1120564T1 (el) 2019-07-10

Family

ID=38833797

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100428T CY1120564T1 (el) 2006-06-23 2018-04-24 Υδατικα εναιωρηματα tmc278

Country Status (32)

Country Link
US (4) US20090176813A1 (el)
EP (2) EP2040671B1 (el)
JP (1) JP5292288B2 (el)
KR (1) KR101406879B1 (el)
CN (1) CN101478950B (el)
AP (1) AP2618A (el)
AR (1) AR061620A1 (el)
AU (1) AU2007262941B2 (el)
BR (2) BRPI0713334B1 (el)
CA (1) CA2654115C (el)
CL (1) CL2007001847A1 (el)
CY (1) CY1120564T1 (el)
DK (1) DK2040671T3 (el)
EA (1) EA021700B1 (el)
ES (1) ES2662068T3 (el)
HR (1) HRP20180629T1 (el)
HU (1) HUE038797T2 (el)
IL (1) IL195491A (el)
JO (1) JOP20200160A1 (el)
LT (1) LT2040671T (el)
MX (1) MX2009000158A (el)
NZ (1) NZ573291A (el)
PE (1) PE20080210A1 (el)
PL (1) PL2040671T3 (el)
PT (1) PT2040671T (el)
RS (1) RS57111B1 (el)
SG (1) SG173315A1 (el)
SI (1) SI2040671T1 (el)
TW (1) TWI413521B (el)
UA (1) UA97641C2 (el)
UY (1) UY30431A1 (el)
WO (1) WO2007147882A2 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
US20110082161A1 (en) * 2008-06-30 2011-04-07 Lieven Elvire Colette Baert Powders for reconstitution
BRPI0923161B1 (pt) * 2008-12-24 2019-01-15 Janssen R&D Ireland dispositivo implantável de uma peça contendo rilpivirina
CN108210469A (zh) 2011-04-15 2018-06-29 詹森药业有限公司 冻干药物纳米混悬剂
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
CN104902905A (zh) 2012-12-14 2015-09-09 葛兰素史克有限责任公司 药物组合物
AU2015323321A1 (en) * 2014-09-26 2017-04-13 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions
TWI678203B (zh) * 2016-05-31 2019-12-01 中裕新藥股份有限公司 蛋白酶抑制劑之長效醫藥組合物
US10369129B2 (en) * 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor
WO2017209732A1 (en) * 2016-05-31 2017-12-07 Taimed Biologics, Inc. A long acting pharmaceutical composition of protease inhibitor
DK3528791T3 (da) 2016-10-24 2024-01-29 Janssen Sciences Ireland Unlimited Co Dispergible sammensætninger
BR112020000687A2 (pt) * 2017-07-14 2020-07-14 Janssen Pharmaceutica Nv formulações de longa ação
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CA3184868A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
PE20231296A1 (es) 2020-07-09 2023-08-22 Janssen Pharmaceutica Nv Formulaciones a largo plazo
CN115776882A (zh) 2020-07-09 2023-03-10 詹森药业有限公司 长效配制品
KR20230110763A (ko) * 2020-11-17 2023-07-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 질환 또는 장애의 치료 또는 예방
UY39520A (es) 2020-11-17 2022-05-31 Janssen Sciences Ireland Unlimited Co Tratamiento o prevención de la infección por vih
TW202333725A (zh) 2021-11-17 2023-09-01 愛爾蘭商健生科學愛爾蘭無限公司 溶出測試
WO2023203258A1 (en) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Liquid compositions
WO2023203255A1 (en) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Freeze dried compositions
WO2023222755A1 (en) 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
WO2023222754A1 (en) 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Rilpivirine for use in the treatment or prevention of hiv infection
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102124A (en) * 1976-07-12 1978-07-25 Swager William E Locking clevis or the like
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5046881A (en) * 1991-02-01 1991-09-10 Swager William E Lockable pin and clevis
US5114260A (en) * 1991-05-13 1992-05-19 Hart Judy L Clevis and screw pin type shackle with pin lock
US5272824A (en) * 1993-05-10 1993-12-28 Caterpillar Inc. Tooth assembly with leaf spring retainer
US5423138A (en) * 1994-04-04 1995-06-13 Caterpillar, Inc. Tip to adapter interface
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CA2383233C (en) * 1999-09-21 2010-06-08 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
WO2003043586A2 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
PT1981506E (pt) * 2006-01-20 2013-06-25 Janssen R & D Ireland Tratamento a longo prazo da infeção pelo vih com tmc278

Also Published As

Publication number Publication date
RS57111B1 (sr) 2018-06-29
CL2007001847A1 (es) 2008-02-08
EA021700B1 (ru) 2015-08-31
HUE038797T2 (hu) 2018-11-28
JP5292288B2 (ja) 2013-09-18
KR20090023703A (ko) 2009-03-05
JP2009541271A (ja) 2009-11-26
DK2040671T3 (en) 2018-05-07
WO2007147882A2 (en) 2007-12-27
US20090176813A1 (en) 2009-07-09
KR101406879B1 (ko) 2014-06-13
US20150010637A1 (en) 2015-01-08
AP2618A (en) 2013-03-18
US20220273653A1 (en) 2022-09-01
CA2654115A1 (en) 2007-12-27
HRP20180629T1 (hr) 2018-06-01
LT2040671T (lt) 2018-05-10
TW200817008A (en) 2008-04-16
AP2008004682A0 (en) 2008-12-31
WO2007147882A3 (en) 2008-06-19
CN101478950A (zh) 2009-07-08
PE20080210A1 (es) 2008-04-11
AR061620A1 (es) 2008-09-10
CN101478950B (zh) 2013-02-06
EA200970047A1 (ru) 2009-04-28
IL195491A0 (en) 2009-09-01
SG173315A1 (en) 2011-08-29
NZ573291A (en) 2011-11-25
TWI413521B (zh) 2013-11-01
US20160089369A1 (en) 2016-03-31
PT2040671T (pt) 2018-03-14
SI2040671T1 (en) 2018-05-31
BRPI0713334B1 (pt) 2024-02-20
EP2040671B1 (en) 2018-01-24
AU2007262941B2 (en) 2013-11-21
UA97641C2 (en) 2012-03-12
PL2040671T3 (pl) 2018-08-31
AU2007262941A1 (en) 2007-12-27
BR122020011487B1 (pt) 2024-02-20
EP2040671A2 (en) 2009-04-01
ES2662068T3 (es) 2018-04-05
BRPI0713334A2 (pt) 2012-03-06
JOP20200160A1 (ar) 2022-10-30
UY30431A1 (es) 2008-01-31
US11389447B2 (en) 2022-07-19
IL195491A (en) 2014-11-30
EP3366278A1 (en) 2018-08-29
CA2654115C (en) 2015-12-22
BRPI0713334A8 (pt) 2018-01-02
MX2009000158A (es) 2009-01-23

Similar Documents

Publication Publication Date Title
CY1120564T1 (el) Υδατικα εναιωρηματα tmc278
CY1120417T1 (el) Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
CY1114089T1 (el) Μακροχρονια θεραπεια της μολυνσης απο hiv με tcm278
CY1117476T1 (el) Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων
CY1122182T1 (el) Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
EA200600877A1 (ru) Наночастицы для доставки лекарств
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1114539T1 (el) Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων
CY1113323T1 (el) Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1124782T1 (el) Φαρμακοτεχνικες μορφες μακρας δρασης
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
CY1121474T1 (el) Συνδυασμος αντιϊικων παραγοντων αμεσης δρασης και ριμπαβιρινης για την θεραπευτικη αγωγη ασθενων me hcv
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
CY1117426T1 (el) Παρεντερικη χορηγηση ταπενταδολης
CY1109120T1 (el) Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης
CY1116374T1 (el) Θεραπεια για τη λοιμωξη με τον ιο της ηπατιτιδας β μονο ή σε συνδυασμο με τον ιο της ηπατιτιδας δελτα και σχετιζομενες ασθενειες του ηπατος
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ